Mr. Aaron Benson reports

ARCH BIOPARTNERS CLOSES NON-BROKERED PRIVATE PLACEMENT

Arch Biopartners Inc. has closed a non-brokered private placement offering of one million common shares priced at 60 cents per common share for gross proceeds of $600,000.

The proceeds of the offering will be used by Arch for general working capital and for certain operating expenses that are not covered by the company's human trial funding grants. The offering is subject to certain conditions including, but not limited to, the receipt of applicable regulatory approvals, including final approval from the TSX Venture Exchange.

The offering involved the issuance of 81,667 common shares to an officer of the company and therefore a related party (as such term is defined under Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions) and therefore constitutes a related party transaction under MI 61-101. This transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to sections 5.5(a) and 5.7(a) of MI 61-101, as the fair market value of the common shares distributed and the consideration received from the related party in the private placement does not exceed 25 per cent of the company's market capitalization.

All common shares issued in connection with the offering will be subject to a hold period of four months and one day from the closing date of April 2, 2026. There were no finders' fees to be paid in connection with the offering.

There is no material fact or material change about the company that has not been generally disclosed.

About Arch Biopartners Inc.

Arch Biopartners is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury.

Arch's development pipeline includes:

• LSALT peptide: in a phase II trial targeting cardiac surgery-associated AKI;
• Cilastatin: a repurposed drug in a phase II trial targeting toxin-induced AKI;
• CKD platform: next-generation therapeutics targeting chronic kidney disease.

These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development.

We seek Safe Harbor.